These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30022802)

  • 1. Patent foramen ovale and cryptogenic stroke: diagnosis and updates in secondary stroke prevention.
    Yuan K; Kasner SE
    Stroke Vasc Neurol; 2018 Jun; 3(2):84-91. PubMed ID: 30022802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients With Cryptogenic Stroke and Patent Foramen Ovale: The IPSYS Registry (Italian Project on Stroke in Young Adults).
    Pezzini A; Grassi M; Lodigiani C; Patella R; Gandolfo C; Zini A; DeLodovici ML; Paciaroni M; Del Sette M; Toriello A; Musolino R; Calabrò RS; Bovi P; Adami A; Silvestrelli G; Sessa M; Cavallini A; Marcheselli S; Marco Bonifati D; Checcarelli N; Tancredi L; Chiti A; Del Zotto E; Tomelleri G; Spalloni A; Giorli E; Costa P; Giacalone G; Ferrazzi P; Poli L; Morotti A; Piras V; Rasura M; Simone AM; Gamba M; Cerrato P; Zedde ML; Micieli G; Melis M; Massucco D; Guido D; De Giuli V; Bonaiti S; D'Amore C; La Starza S; Iacoviello L; Padovani A;
    Circ Cardiovasc Interv; 2016 Sep; 9(9):. PubMed ID: 27582111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent events after percutaneous closure of patent foramen ovale.
    Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
    Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
    Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke.
    Kent DM; Thaler DE;
    Trials; 2011 Jul; 12():185. PubMed ID: 21794121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
    Mas JL; Derex L; Guérin P; Guillon B; Habib G; Juliard JM; Marijon E; Massardier E; Meneveau N; Vuillier F
    Arch Cardiovasc Dis; 2019; 112(8-9):532-542. PubMed ID: 31378692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
    Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Closure of Patent Foramen Ovale in Preventing Subsequent Neurological Events: A Bayesian Network Meta-Analysis to Identify the Best Device.
    Varotto L; Bregolin G; Paccanaro M; De Boni A; Bonanno C; Perini F
    Cerebrovasc Dis; 2020; 49(2):124-134. PubMed ID: 32289794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of recurrent stroke after percutaneous closure of patent foramen ovale.
    Rudolph V; Augustin J; Hofmann T; Hamm CW; Meinertz T; Köster R; Baldus S; Franzen O
    EuroIntervention; 2014; 9(12):1418-22. PubMed ID: 24169021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Transcatheter Closure of Patent Foramen Ovale.
    Neill J; Lin CH
    Methodist Debakey Cardiovasc J; 2017; 13(3):152-159. PubMed ID: 29744000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update.
    Arfaras-Melainis A; Palaiodimos L; Mojadidi MK
    Interv Cardiol Clin; 2019 Oct; 8(4):341-356. PubMed ID: 31445719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
    Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.
    Horlick E; Kavinsky CJ; Amin Z; Boudoulas KD; Carroll JD; Hijazi ZM; Leifer D; Lutsep HL; Rhodes JF; Tobis JM
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):859-874. PubMed ID: 30896894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Fragility Index in Randomized Controlled Trials for Patent Foramen Ovale Closure in Cryptogenic Stroke.
    Topcuoglu MA; Arsava EM
    J Stroke Cerebrovasc Dis; 2019 Jun; 28(6):1636-1639. PubMed ID: 30890394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.